2:45 p.m. Thursday
The Nasdaq, which had sent Oxygen Biotherapeutics, a delisting notice in March, gives the company more time to show it meets listing requirements.
Oxygen Biotherapeutics' (NASDAQ:OXBT) recent securities offering net $1.9 million -- enough to open clinical trial sites in Switzerland and Israel to study traumatic brain injury drug candidate Oxycyte. Beyond must take other financial steps.
November 21, 2012
Oxygen Biotherapeutics picks PPD as the contract research organization to run a Phase 2 clinical trial on a proposed treatment for traumatic brain injury.
August 29, 2012
The drug firm has closed a facility in California and says it is seeking lab space in the Triangle.
July 26, 2012
Oxygen Biotherapeutics reported this week a net loss of $15.7 million for its recently completed fiscal year, up from a net loss of $10.4 million a year ago. Total net revenue did rise, though, to nearly $364,000 from last year.
March 2, 2012
Oxygen Biotherapeutics says it will focus on sales of its skin product in North Carolina and South Florida.
February 2, 2012
In an ischemic stroke, a clot blocks a vessel to the brain and deprives it of oxygen. Stroke treatments aim to salvage as much of the surrounding, salvageable brain tissue as possible.
December 13, 2011
The funding follows a shakeup at Oxygen's executive offices and board. Former Chairman and CEO Chris Stern's positions at the company were terminated in August following an internal investigation that concluded Stern lied about his academic background and conducted undisclosed securities deals that he tried to cover up. Shortly afterward, two members of Oxygen's board of directors resigned after shareholders withheld their votes for the two directors.
October 11, 2011
Two board members resign in the wake of disclosures of alleged improprieties leading to the ouster of former CEO Chris Stern.
August 26, 2011
The Morrisville-based developer of oxygen-based health products dismisses Chairman and CEO Chris Stern after audit investigation.
Updated July 26, 2011
The two firms plan to partner on preclinical research into combating strokes.
Updated November 3, 2010
The Durham-based drug development firm is developing a treatment targeting brain and spinal cord injuries.
Updated March 30, 2010
In SEC filing, the Durham-based firm says it also is seeking other financing and alliances. OxyBio also begins distribution of a new over-the-counter skin care product.